Clinical Application of Indobufen in the Treatment of Antiplatelet

Abstract

Abstract:

Thromboembolic disease seriously threatens human's life and health and quality of life, and antiplatelet therapy is an important means of treatment for thromboembolic disease. As one kind of antiplatelet agents, indobufen is remarkable in the treatment and prevention for thromboembolic disease. This article summarizes the secondary prevention effects of indobufen for thromboembolic events in patients with high risk, the treatment for other thromboembolic diseases, and the patency maintenance function for grafts or coronary artery after interventions, with the aim to guide the clinical practice.

Key words: Indobufen; Thromboembolic disease; Antiplatelet

摘要：

血栓栓塞性疾病严重威胁着人类的生命健康和生活质量，而抗血小板治疗是治疗血栓栓塞性疾病的重要手段，其中吲哚布芬作为一种抗血小板药物，对于治疗及预防血栓栓塞性疾病有一定的疗效。现就吲哚布芬对高危患者血栓栓塞事件的二级预防作用及其他血栓栓塞性疾病的治疗价值，对移植血管或介入术后冠状动脉通畅性的维持作用方面做一综述，以期指导临床。

关键词: 吲哚布芬; 血栓栓塞性疾病; 抗血小板

WU Hao, BI Qi.. Clinical Application of Indobufen in the Treatment of Antiplatelet[J]. Chinese Journal of Stroke, 2013, 8(09): 773-776.

吴昊，毕齐. 吲哚布芬在抗血小板治疗中的临床应用[J]. 中国卒中杂志, 2013, 8(09): 773-776.

References

1 胡大一, 孙艺红. 贯彻循证医学原则重视血栓栓塞性疾病的防治[J]. 中华医学杂志, 2005:2163-2168.

2 Tamassia V, Corvi G, Fuccella LM, et al. Indobufen (K 3920), a new inhibitor of platelet aggregation:effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man[J]. Eur J Clin Pharmacol, 1979, 15:329-333.

3 Patrono C, Baigent C, Hirsh J, et al. Antiplatelet drugs:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)[J]. Chest, 2008, 133:199S-233S.

4 Battaglia A, Stragliotto E, Heiman F, et al. Indobufen in the secondary prevention of cerebral ischemic attack (TIA):A prospective, randomized, controlled study[J]. Thromb Haemost, 1993, 69:1349-1358.

5 Bergamasco B, Benna P, Carolei A, et al. A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study[J]. Funct Neurol, 1997, 12:33-43.

6 杨进刚. 心房颤动的诊断与药物治疗(中国专家共识)[J]. 心脑血管病防治, 2008, 8:215-222.

7 Fornaro G, Rossi P, Mantica PG, et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study[J]. Circulation, 1993, 87:162-164.

8 Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators[J]. Stroke, 1997, 28:1015-1021.

9 Belcaro G, Errichi BM, De Simone P. Prevention of recurrent deep venous thrombosis with indobufen. A 3-year follow-up study using color duplex scanning[J]. Angiology, 1993, 44:328-331.

10 Cataldo G, Heiman F, Lavezzari M, et al. Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery:results of a combined analysis[J]. Coron Artery Dis, 1998, 9:217-222.

11 Barillà F, Pulcinelli FM, Mangieri E, et al. Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention[J]. Platelets, 2013, 24:183-188.

12 温继梨, 崔晓迎. 吲哚布芬应用于PCI术后预防冠状动脉再狭窄的研究[J]. 湖南中医药大学学报, 2012, 32:29-30.

[1]	LI Zhenhua, LIU Zhu, HU Quanzhong. Progress in Drugs Therapy for Non-disabling Ischemic Cerebrovascular Events [J]. Chinese Journal of Stroke, 2022, 17(04): 407-412.
[2]	ZHANG Junliang, HUANG Shuangfeng, XU Luyao, XIANG Wei, ZHANG Manman, LIANG Zhigang. Safety and Efficacy of Tirofiban in the Treatment of Mild to Moderate Non-Cardiogenic Ischemic Stroke Screened by MRI [J]. Chinese Journal of Stroke, 2022, 17(01): 66-72.
[3]	WANG Cong-Jie, LI Hong, ZHENG Li, LIU Shan, LU Hai-Li, CHEN Na, ZHANG Bin, ZHOU Heng. Efficacy of Dual Antiplatelet Therapy after Intravenous Thrombolysis in Patients with Mild Ischemic Stroke [J]. Chinese Journal of Stroke, 2021, 16(10): 1044-1049.
[4]	YU Yi-Jiao, LIU Li, DU Juan, LI Wei, LIN Tian,LU Dong-Xu, CAI Yi-Ling. Clinical Features and Prognosis of Capsule Warning Syndrome [J]. Chinese Journal of Stroke, 2020, 15(12): 1317-1321.
[5]	MA Gao-Ting, MIAO Zhong-Rong. Antiplatelet Therapy in Endovascular Treatment for Ischemic Cerebrovascular Disease [J]. Chinese Journal of Stroke, 2020, 15(02): 202-208.
[6]	Wang Yi-Long. Strategy Selection of Antiplatelet Therapy for Ischemic Stroke in terms of the Ethnic Differences between Easterners and Westerners [J]. Chinese Journal of Stroke, 2018, 13(05): 494-499.
[7]	WANG Jin-Peng, ZHANG Hao, LEI Yan-Cheng, et al.. The Outcome and Correlation Analysis of Plateau Unruptured Intracranial Wide-necked Aneurysms Stent Assisted Coil Embolization Treatment for 3 Years and Drug Treatment [J]. Chinese Journal of Stroke, 2016, 11(05): 355-359.
[8]	LIU Dong-Tao, ZHOU Li-Chun. Clinical Study of Select Different Anti-platelet Drugs in Patients with Acute Non-cardiogenic Cerebral Infarction according to Thromboelastography [J]. Chinese Journal of Stroke, 2015, 10(12): 1006-1011.
[9]	WANG Huan,LI Wei, LIU Cheng-Chun, WU Ya, YI Xu, ZHANG Zhi-Hong, LI Xiao-Shu, ZHANG Meng.. Assessing the Safety of Selectively Early Administration of Dual Antiplatelet Therapy in Patients with Cerebral Infarction after Intravenous Thrombolysis [J]. Chinese Journal of Stroke, 2014, 9(10): 831-836.
[10]	HUANG Wei, BI Qi.. New Progress in Transient Ischemic Attack [J]. Chinese Journal of Stroke, 2014, 9(10): 874-879.